Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?

PURPOSE OF REVIEW We summarize MRI measures currently available to assess treatment efficacy and safety in multiple sclerosis (MS) clinical trials and discuss novel metrics that could enter the clinical arena in the near future. RECENT FINDINGS In relapsing remitting MS, MRI measures of disease activity (new T2 and gadolinium-enhancing lesions) provide a good surrogacy of treatment effect on relapse rate and disability progression; however, their value in progressive MS remains elusive. For the progressive disease forms, these measures need to be combined with quantities assessing the extent of irreversible tissue loss, which have already been introduced in some clinical trials (e.g., evolution of active lesions into permanent black holes and brain atrophy). Novel measures (e.g., quantification of gray matter and spinal cord atrophy) have demonstrated a great value in explaining patients' clinical outcome, but still need to be fully validated. Despite showing promise, evaluations of cortical lesions, of microscopic tissue abnormalities, and of functional cortical reorganization are still some way off for monitoring of treatment effects. SUMMARY Trial outcomes in MS should include measures of inflammation and neurodegeneration, which should be combined according to the disease clinical phenotype, phase of the study, and the supposed mechanism of action of the drug tested.

[1]  J K Udupa,et al.  Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS , 2000, Neurology.

[2]  M. Filippi,et al.  European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. , 2004, Archives of neurology.

[3]  G. Comi,et al.  Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  E. Radue,et al.  Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a , 2005, Neurology.

[5]  Elizabeth Fisher,et al.  Clinically feasible MTR is sensitive to cortical demyelination in MS , 2013, Neurology.

[6]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[7]  M. Sormani,et al.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.

[8]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[9]  D. Arnold,et al.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis , 2006, Neurology.

[10]  M. Horsfield,et al.  Gray matter damage predicts the accumulation of disability 13 years later in MS , 2013, Neurology.

[11]  F. Barkhof,et al.  Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis , 2010, Multiple sclerosis.

[12]  D. Arnold,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[13]  M. Calabrese,et al.  Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis , 2012, Multiple sclerosis.

[14]  F. Barkhof,et al.  Postmortem verification of MS cortical lesion detection with 3D DIR , 2012, Neurology.

[15]  P. Matthews,et al.  Relating Brain Damage to Brain Plasticity in Patients With Multiple Sclerosis , 2012, Neurorehabilitation and neural repair.

[16]  M. Filippi,et al.  Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy , 2012, Annals of neurology.

[17]  M. Calabrese,et al.  Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis , 2012, Multiple sclerosis.

[18]  M. Filippi,et al.  Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures--an explorative study. , 2012, Radiology.

[19]  Ludwig Kappos,et al.  Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials , 1997, Journal of Neurology.

[20]  L. Kappos,et al.  Evolution of MS lesions to black holes under DNA vaccine treatment , 2012, Journal of Neurology.

[21]  L. Kappos,et al.  MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS , 2007, Neurology.

[22]  D. Goodin.  Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? , 2006, Annals of neurology.

[23]  M. Horsfield,et al.  A multicenter assessment of cervical cord atrophy among MS clinical phenotypes , 2011, Neurology.

[24]  Luca Roccatagliata,et al.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach , 2009, Annals of neurology.

[25]  M. Battaglini,et al.  Modelling the distribution of cortical lesions in multiple sclerosis , 2012, Multiple sclerosis.

[26]  P. Narayana,et al.  Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study , 2008, Multiple sclerosis.

[27]  Zografos Caramanos,et al.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b , 2001, Journal of Neurology.

[28]  M. Filippi,et al.  The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study , 2007, Multiple sclerosis.

[29]  Ludwig Kappos,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[30]  P M Matthews,et al.  Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi‐centre fMRI study , 2008, European journal of neurology.

[31]  Derek K. Jones,et al.  Neuroplasticity and functional recovery in multiple sclerosis , 2012, Nature Reviews Neurology.

[32]  M. Battaglini,et al.  Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.

[33]  N. Richert.  Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". , 2002, Neurology.

[34]  M. Horsfield,et al.  Ultra-high-field MR imaging in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  J. Skurnick,et al.  New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  N. De Stefano,et al.  Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment , 2004, Neurology.

[37]  D. Miller,et al.  Interferon β-1a in primary progressive MS , 2003, Neurology.

[38]  L. Kappos,et al.  Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. , 2012, Archives of neurology.

[39]  M. Filippi,et al.  Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  D. Arnold,et al.  Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials , 2013, Neurology.

[41]  P. Matthews,et al.  Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study , 2009, Human brain mapping.

[42]  Marco Rovaris,et al.  Intercenter differences in diffusion tensor MRI acquisition , 2010, Journal of magnetic resonance imaging : JMRI.

[43]  M Filippi,et al.  Spinal cord atrophy and disability in multiple sclerosis over four years , 2003, Journal of neurology, neurosurgery, and psychiatry.

[44]  G. Stebbins,et al.  A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis , 2009, Journal of Neuroimmunology.

[45]  G. Comi,et al.  Interferon β-1b and glatiramer acetate effects on permanent black hole evolution , 2011, Neurology.

[46]  P. Matthews,et al.  Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability , 2011, Multiple sclerosis.

[47]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[48]  M. Filippi,et al.  Intracortical lesions , 2010, Neurology.

[49]  L. Roccatagliata,et al.  Surrogate endpoints for EDSS worsening in multiple sclerosis , 2010, Neurology.

[50]  Ludwig Kappos,et al.  Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. , 2013, Radiology.

[51]  J. Duda,et al.  Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a , 2000, Multiple sclerosis.

[52]  Douglas L. Arnold,et al.  Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis , 2013, NeuroImage.

[53]  A. Thompson,et al.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.

[54]  F. Barkhof,et al.  The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study , 2002, Multiple sclerosis.

[55]  M. A. Horsfield,et al.  Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis , 2010, NeuroImage.

[56]  F. X. Aymerich,et al.  A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis , 2009, Multiple sclerosis.

[57]  P. Matthews,et al.  Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis , 2009, Journal of psychopharmacology.

[58]  D. Altmann,et al.  Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine , 2012, Journal of Neurology.

[59]  David H. Miller,et al.  Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.

[60]  David H. Miller,et al.  MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials , 2012, Nature Reviews Neurology.

[61]  M Filippi,et al.  MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b , 2003, Neurology.

[62]  D. Altmann,et al.  Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab , 2013, Multiple sclerosis.

[63]  N. De Stefano,et al.  Clinical use of brain volumetry , 2013, Journal of magnetic resonance imaging : JMRI.

[64]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[65]  J A Frank,et al.  Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis , 1998, Annals of neurology.

[66]  F. Barkhof,et al.  A three-year, multi-parametric MRI study in patients at presentation with CIS , 2008, Journal of Neurology.

[67]  P M Matthews,et al.  Guidelines for using proton MR spectroscopy in multicenter clinical MS studies , 2007, Neurology.

[68]  M. Sormani,et al.  Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis , 2011, Neurology.

[69]  David H. Miller,et al.  Improved MRI quantification of spinal cord atrophy in multiple sclerosis , 2011, Journal of magnetic resonance imaging : JMRI.

[70]  David H. Miller,et al.  Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis , 2004, Journal of Neurology.

[71]  Robert A. Gross,et al.  Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI , 2011 .

[72]  F. Barkhof,et al.  Cortical imaging in multiple sclerosis: recent findings and 'grand challenges'. , 2013, Current opinion in neurology.

[73]  D. Chard,et al.  Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. , 2003, Neurology.

[74]  M. Filippi,et al.  MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients , 2002, Neurology.

[75]  F. Barkhof,et al.  The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS , 2003, Neurology.